Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

ClinicalTrials.gov ID: NCT01740297

Public ClinicalTrials.gov record NCT01740297. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 1b of the study will evaluate the safety of talimogene laherparepvec in combination with ipilimumab. Phase 2 is a randomized study that will evaluate the safety and efficacy of talimogene laherparepvec in combination with ipilimumab versus ipilumumab alone.

Study identification

NCT ID
NCT01740297
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Amgen
Industry
Enrollment
217 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 7, 2013 (Actual)
Primary completion
Aug 23, 2016 (Actual)
Completion
Mar 9, 2021 (Actual)
Last update posted
May 14, 2024

2013 – 2021

United States locations

U.S. sites
32
U.S. states
20
U.S. cities
27
Facility City State ZIP Site status
Research Site Tucson Arizona 85724 —
Research Site Beverly Hills California 90211 —
Research Site Los Angeles California 90025 —
Research Site Los Angeles California 90089-2211 —
Research Site Los Angeles California 90095 —
Research Site San Francisco California 94115 —
Research Site Santa Rosa California 95403 —
Research Site Aurora Colorado 80045 —
Research Site Jacksonville Florida 32207 —
Research Site Jacksonville Florida 32224 —
Research Site Lakeland Florida 33805 —
Research Site Miami Florida 33140 —
Research Site Chicago Illinois 60612 —
Research Site Indianapolis Indiana 46202 —
Research Site Indianapolis Indiana 46260 —
Research Site Iowa City Iowa 52242 —
Research Site Louisville Kentucky 40202 —
Research Site Minneapolis Minnesota 55407 —
Research Site St Louis Missouri 63110 —
Research Site Morristown New Jersey 07962 —
Research Site New Brunswick New Jersey 08903 —
Research Site New York New York 10029 —
Research Site New York New York 10032 —
Research Site Chapel Hill North Carolina 27599 —
Research Site Canton Ohio 44718 —
Research Site Cincinnati Ohio 45267 —
Research Site Charleston South Carolina 29425 —
Research Site Nashville Tennessee 37232 —
Research Site Houston Texas 77030 —
Research Site Salt Lake City Utah 84112 —
Research Site Richmond Virginia 23298-0037 —
Research Site Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01740297, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 14, 2024 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01740297 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →